Zevra Therapeutics (NASDAQ:ZVRA) Shares Gap Up – Should You Buy?

Zevra Therapeutics, Inc. (NASDAQ:ZVRA)’s stock price gapped up before the market opened on Tuesday . The stock had previously closed at $9.12, but opened at $10.95. Zevra Therapeutics shares last traded at $10.9820, with a volume of 4,095,664 shares traded.

Wall Street Analysts Forecast Growth

Several research analysts have weighed in on ZVRA shares. Guggenheim set a $23.00 price target on Zevra Therapeutics and gave the stock a “buy” rating in a research note on Tuesday. Weiss Ratings reiterated a “sell (d+)” rating on shares of Zevra Therapeutics in a report on Friday, January 9th. Finally, HC Wainwright set a $26.00 price objective on shares of Zevra Therapeutics in a report on Tuesday, December 30th. Six investment analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has given a Sell rating to the company. According to data from MarketBeat.com, Zevra Therapeutics has an average rating of “Moderate Buy” and an average target price of $23.00.

Zevra Therapeutics Price Performance

The company has a quick ratio of 8.57, a current ratio of 8.62 and a debt-to-equity ratio of 0.46. The company has a market capitalization of $626.90 million, a PE ratio of 23.52 and a beta of 0.91. The firm’s 50 day simple moving average is $8.80 and its 200 day simple moving average is $9.06.

Insider Transactions at Zevra Therapeutics

In other news, CEO Neil F. Mcfarlane sold 91,000 shares of the firm’s stock in a transaction on Monday, February 2nd. The stock was sold at an average price of $9.38, for a total transaction of $853,580.00. Following the transaction, the chief executive officer owned 364,350 shares in the company, valued at approximately $3,417,603. This trade represents a 19.98% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is accessible through this link. Also, SVP Timothy J. Sangiovanni sold 3,000 shares of the company’s stock in a transaction dated Tuesday, February 3rd. The stock was sold at an average price of $9.18, for a total transaction of $27,540.00. Following the completion of the sale, the senior vice president directly owned 29,590 shares of the company’s stock, valued at approximately $271,636.20. This trade represents a 9.21% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Insiders sold a total of 114,158 shares of company stock worth $1,062,878 over the last quarter. 2.40% of the stock is owned by corporate insiders.

Institutional Inflows and Outflows

Large investors have recently made changes to their positions in the stock. CWM LLC lifted its position in shares of Zevra Therapeutics by 399.5% during the third quarter. CWM LLC now owns 2,872 shares of the company’s stock valued at $27,000 after buying an additional 2,297 shares during the last quarter. Ameritas Investment Partners Inc. raised its stake in shares of Zevra Therapeutics by 30.0% during the 2nd quarter. Ameritas Investment Partners Inc. now owns 5,541 shares of the company’s stock worth $49,000 after acquiring an additional 1,280 shares in the last quarter. Gunpowder Capital Management LLC dba Oliver Wealth Management purchased a new stake in Zevra Therapeutics during the fourth quarter valued at approximately $53,000. Russell Investments Group Ltd. boosted its stake in Zevra Therapeutics by 235.7% in the third quarter. Russell Investments Group Ltd. now owns 6,374 shares of the company’s stock valued at $61,000 after acquiring an additional 4,475 shares in the last quarter. Finally, Tower Research Capital LLC TRC grew its holdings in Zevra Therapeutics by 617.5% in the second quarter. Tower Research Capital LLC TRC now owns 9,937 shares of the company’s stock worth $88,000 after purchasing an additional 8,552 shares during the last quarter. 35.03% of the stock is owned by institutional investors.

Zevra Therapeutics Company Profile

Zevra Therapeutics, Inc discovers and develops various proprietary prodrugs to treat serious medical conditions in the United States. The company develops its products through Ligand Activated Therapy platform. Its lead product candidate is KP1077, consisting of KP1077IH, which is under Phase 2 clinical trial for the treatment of idiopathic hypersomnia, and KP1077N, which is under Phase ½ clinical trial to treat narcolepsy. The company is also developing Celiprolol, a prodrug product candidate that is under Phase 1/2 clinical trial for the treatment of vascular Ehlers Danlos syndrome.